To the Editor: In the final, 10-year outcomes of the CheckMate 067 trial reported by Wolchok et al. (Jan. 2 issue), 1 the combination of nivolumab and ipilimumab resulted in an unprecedented ...
There were 11 hypersensitivity reactions, all in patients receiving nivolumab. Reducing the infusion time for nivolumab and pembrolizumab to 10 minutes is feasible and safe, according to researchers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback